We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · December 30, 2020

Effects of Dapagliflozin on Major Adverse Kidney and Cardiovascular Events in Patients With Chronic Kidney Disease

The Lancet Diabetes & Endocrinology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Diabetes & Endocrinology
Effects of Dapagliflozin on Major Adverse Kidney and Cardiovascular Events in Patients With Diabetic and Non-Diabetic Chronic Kidney Disease: A Prespecified Analysis From the DAPA-CKD Trial
Lancet Diabetes Endocrinol 2021 Jan 01;9(1)22-31, DC Wheeler, BV Stefánsson, N Jongs, GM Chertow, T Greene, FF Hou, JJV McMurray, R Correa-Rotter, P Rossing, RD Toto, CD Sjöström, AM Langkilde, HJL Heerspink

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading